22 studies found for:    stx209
Show Display Options
Download search resultsDownload the search results for:
stx209 (22 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting MEG Study of STX209
Condition: Autism Disorder
Interventions: Drug: STX209;   Drug: placebo
2 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
3 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
4 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
5 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
6 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
7 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
8 Completed Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Arbaclofen placarbil 15 mg BID;   Drug: Placebo;   Drug: Arbaclofen placarbil 30 mg BID;   Drug: Arbaclofen placarbil 45 mg BID
9 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
10 Completed A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: arbaclofen placarbil-Cohort 1;   Drug: Placebo-Cohort 5;   Drug: arbaclofen placarbil-Cohort 2;   Drug: arbaclofen placarbil-Cohort 3;   Drug: arbaclofen placarbil-Cohort 4;   Drug: PPI
11 Completed A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
Condition: Alcohol Use Disorder
Interventions: Drug: Arbaclofen Placarbil;   Drug: Placebo
12 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
13 Completed Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Conditions: Spasticity;   Multiple Sclerosis
Interventions: Drug: arbaclofen;   Drug: baclofen;   Drug: Placebo
14 Completed One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Conditions: Multiple Sclerosis;   Spasticity
Intervention: Drug: arbaclofen
15 Completed Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Condition: Fragile X Syndrome
Intervention: Drug: STX209
16 Completed A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Condition: Back Spasms
Interventions: Drug: Arbaclofen placarbil, 20 mg BID;   Drug: Placebo;   Drug: Arbaclofen placarbil, 30 mg BID;   Drug: Arbaclofen placarbil, 40 mg BID
17 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209
18 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
19 Completed A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
Condition: GERD
Interventions: Drug: XP19986 CR;   Drug: Placebo for XP19986 CR
20 Completed An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
Condition: Gastroesophageal Reflux
Interventions: Drug: XP19986 SR3, 20 mg QD;   Drug: XP19986 SR3, 40 mg QD;   Drug: XP19986 SR3, 60 mg QD;   Drug: XP19986 SR3, 30 mg BID;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years